Diabetes is a significant social problem, since it leads both to disability and high mortality rate. The experiment involved 32 sexually mature nonlinear males of white rats. Experimental groups of animals were administered a single streptozotocin dose of 70 mg/kg intraperitoneally and NADP – 30 mg/kg. The animals in the experimental groups were slaughtered and studied on the 11^th, 21^st and 31^st days after streptozotocin administration. The studies have shown that NADP affects the metabolism, reduces the production of acids and, as a result, reduces the excretion of acids by the kidneys in experimental animals.

Bequer L, Gómez T, Molina JL. Streptozotocin diabetogenic action in an experimental neonatal induction model. Biomedica. 2016;36(2):230-8.

Boonloh K, Lee ES, Kim, Hong M, Kwon MH, Kim YM, Pannangpetch P. Rice bran protein hydrolysates attenuate diabetic nephropathy in diabetic animal model. European journal of nutrition. 2016;1-12. DOI:10.1007/s00394-016-1366-y.

Dudar IO. Mekhanizmy rozvytku ta prohresuvannia diabetychnoi nefropatii [Mechanisms of development and progression of diabetic nephropathy]. Klinichna imunolohiia. Alerholohiia. Infektolohiia. 2010;9-10:46-50.

El Din UAAS, Salem MM, Abdulazim DO. Diabetic nephropathy: Time to withhold development and progression A review. Journal of advanced research. 2017;8(4):363-73. doi: 10.1016/j.jare.2017.04.004.

Herrera GA, Turbat-Herrera EA, Teng J. Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis. Nephron. 2016;132(2):119-36.

Liu X, Mo Y, Gong J. Puerarin ameliorates cognitive deficits in streptozotocin-induced diabetic rats. Metab. Brain Dis. 2016;31(2):417-23.

Mohammad S, Basel M, Abozor L, Khalid H, Zawawi G. The relationship between periapical lesions and the serum levels of glycosylated hemoglobin and C-reactive protein in type 2 diabetic patients. Saudi Med. J. 2017;1(38): 36-40.

Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, Górriz JL, Martínez-Castelao A, Navarro-González JF. Diabetic kidney disease: from physiology to therapeutics. J Physiol. 2014;592(18):3997-4012. doi: 10.1113/jphysiol.2014.272328.

Romero MJ, Lucas R, Dou H. Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. Proc. Natl. Acad Sci USA. 2016;113(7):1895-1900.

Sen Zh, Dongjie W, Nina X. Nicousamide protects kidney podocyte by inhibiting the TGFβ receptor II phosphorylation and AGE-RAGE signaling. Am. J. Transl. Res. 2017;9(1):115-25.

Yefimov AS, Skrobonska NA, Tsymbal TS. Patohenetychni markery u rozvytku diabetychnoi nefropatii u khvorykh na tsukrovyi diabet typu 1, yikh znachennia u rannii diahnostytsi ta optymizatsii likuvannia [Pathogenetic markers in the development of diabetic nephropathy in patients with type 1 diabetes mellitus, their importance in early diagnosis and optimization of treatment ]. Endokrynolohiia. 2014;19(4):295-6.